Stockscreener 앱 받기
2.12
1.40%
-0.03
전일 마감가:
$2.15
열려 있는:
$2.14
하루 거래량:
21,385
Relative Volume:
0.24
시가총액:
$86.60M
수익:
$2.70M
순이익/손실:
$5.53M
주가수익비율:
19.27
EPS:
0.11
순현금흐름:
$-10.55M
1주 성능:
-1.40%
1개월 성능:
-8.23%
6개월 성능:
-9.40%
1년 성능:
-8.62%
1일 변동 폭
$2.1101
$2.19
1주일 범위
$2.09
$2.19
52주 변동 폭
$1.82
$3.09
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
명칭
Oramed Pharmaceuticals Inc
전화
646-844-1164
주소
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
ORMP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.12 | 87.83M | 2.70M | 5.53M | -10.55M | 0.11 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-12 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-20 | 개시 | Canaccord Genuity | Buy |
| 2021-02-09 | 개시 | National Securities | Buy |
| 2020-12-03 | 개시 | Alliance Global Partners | Buy |
| 2020-03-11 | 개시 | Aegis Capital | Buy |
| 2019-09-11 | 개시 | Ladenburg Thalmann | Buy |
| 2017-12-11 | 재개 | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | 재확인 | FBR Capital | Outperform |
| 2015-12-01 | 재확인 | H.C. Wainwright | Buy |
| 2015-11-19 | 개시 | FBR Capital | Outperform |
| 2015-04-13 | 재개 | MLV & Co | Buy |
| 2014-01-30 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 재확인 | Aegis Capital | Buy |
| 2014-01-08 | 개시 | MLV & Co | Buy |
| 2013-12-03 | 개시 | Aegis Capital | Buy |
모두보기
Oramed Pharmaceuticals Inc 주식(ORMP)의 최신 뉴스
Oramed Pharm Extends Stock Buyback Program - TipRanks
Dimensional Fund Advisors LP Grows Stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - Defense World
Oramed: Q1 Earnings Snapshot - New Haven Register
Alpha Tau Medical appoints new board member By Investing.com - Investing.com India
Alpha Tau Medical appoints new board member - Investing.com
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors - GlobeNewswire
StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Sell - Defense World
Renaissance Technologies LLC Trims Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
LPL Financial LLC Sells 21,250 Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize
Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus
Oramed invests $36.9 million in Alpha Tau cancer therapy By Investing.com - Investing.com
Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals - Nasdaq
Oramed Pharmaceuticals Announces $36.9 Million Investment And Strategic Collaboration With Alpha Tau Medical - marketscreener.com
Alpha Tau Announces Closing of $36.9 Million Registered - GlobeNewswire
Major Biotech Deal: Alpha Tau Medical Secures $36.9M Investment to Accelerate Cancer Treatment Innovation - Stock Titan
Oramed Closes $36.9M Strategic Investment in Alpha Tau Medical - citybiz
Alpha Tau's $37M Deal Unlocks Major Growth: 4 US Trials and Marketing Alliance Signal Expansion - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
ORMPOramed Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
What To Expect From Tesla’s (TSLA) Q1 Earnings - The Globe and Mail
Oramed stock hits 52-week low at $1.95 amid market challenges - Investing.com Australia
Oramed stock hits 52-week low at $1.95 amid market challenges By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Inc. (ORMP) reports earnings - Quartz
Oral Biologics Market Is Booming Worldwide 2025-2032 | Biocon - openPR.com
Oramed Pharmaceuticals Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St
Oramed Pharmaceuticals Stock Plummets After Insulin Test Results - The Wall Street Journal
Tianhui Biotech and Oramed Pharmaceuticals’ Investment in OraTech Pharmaceuticals - Global Legal Chronicle
AllPennyStocks.com Releases a Special Report on Oramed Pharmaceuticals Inc. - ACCESS Newswire
Oramed advances oral insulin, plans Phase 3 trial and dividend - Investing.com
Oramed advances oral insulin, plans Phase 3 trial and dividend By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Issues Letter to Shareholders - PR Newswire
ORMP stock touches 52-week low at $2 amid market challenges By Investing.com - Investing.com South Africa
ORMP stock touches 52-week low at $2 amid market challenges - Investing.com
Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expands By 149.0% - Armenian Reporter
OraMed Enters Global Licensing Deal for Lidocaine Product By Investing.com - Investing.com Australia
Oramed Pharmaceuticals (ORMP) to Release Quarterly Earnings on Wednesday - MarketBeat
OraMed Enters Global Licensing Deal for Lidocaine Product - Investing.com India
Rep. Brad Knott Sells Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares - MarketBeat
Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock - Benzinga
Congress Trade: Representative Brad Knott Just Disclosed New Stock Trades - Quiver Quantitative
Oramed Pharmaceuticals Inc (ORMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
17.27%
1.06%
자본화:
|
볼륨(24시간):